ThinkEquity piles on to Navidea's (NAVB -27.4%) travails today, downgrading the shares to Hold on the back of the FDA's rejection of its Lymphoseek application and lack any of visibility on the FDA's review process going forward. The firm also slashes its price target to $2.50 from $7.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs